[286 Pages Report] The global monoclonal antibodies market was valued at US$ 186 Billion in 2021 and is projected to exhibit a CAGR of 12% from 2022 to 2032. The rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and others is increasing the demand for biologics, which is anticipated to serve as a key factor driving the monoclonal antibodies (mAbs) market. Similarly, increasing applications of mAb therapies for targeted therapies and rising awareness about such therapies amongst patients and physicians is expected to significantly contribute toward the market growth.
Increased usage of Monoclonal antibodies in the treatment of many cancers in industrialized countries, is leading to a rapid rise in the worldwide monoclonal antibody market. As per the GLOBOCAN 2020 research, there were 19.3 million new cancer diagnoses and approximately 10 million cancer-related deaths worldwide.
In order to control the rising number, research & development activities in the market are creating new opportunities. New gene-based therapy, new research related to the application of monoclonal antibodies in treating other deadly diseases, such as COVID-19, disease diagnostics, and treatment of other diseases, including auto-immune, viral disease treatment, and government approval of new antibodies may all contribute to the market's growth.
For instance, Union Chimique Belge (UCB) signed a license agreement with Roche and Genentech in July 2020 for the manufacturing and commercialization of UCB0107, a potent monoclonal antibody for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's disease, but it is still being studied.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2021) | US$ 186 Billion |
| Expected Market Value (2022) | US$ 208.32 Billion |
| Anticipated Forecast Value (2032) | US$ 647.01 Billion |
| Projected Growth Rate (2022 to 2032) | 12% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for Monoclonal Antibodies is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%.
Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.
Humanized mAbs are expected to reveal the fastest CAGR in the forecast period due to their widespread use against a broad range of target antigens such as cancer cells, immunosuppression, and immunomodulatory molecules. Demand for such antibodies is also supported by their lower immunogenicity as compared to chimeric mAbs. However, these antibodies are more immunogenic as compared to human mAbs, which may restrict the market growth.
Extensive Uptake during the Pandemic Crisis for Developing Drugs provided a Major Boost in past years
The COVID-19 pandemic has increased the market expansion prospects by fueling the development of several mAbs directed against the SARS-CoV-2 virus. As mAbs represent a promising alternative for the mitigation of COVID-19 due to their safety and effectiveness, several such antibodies have attained emergency use authorizations (EUA) from the U.S. FDA. For instance, in February 2022, the U.S. FDA granted a EUA to Eli Lilly’s bebtelovimab for the treatment of COVID-19 patients that are at risk of developing severe disease or who may need hospitalization.
In addition, the U.S. Department of Health and Human Services announced the distribution of at least 600,000 free bebtelovimab courses, along with an optional purchase of 500,000 additional doses in the future, thus creating new opportunities for growth of mAbs/Key advantages offered by mAb therapies over previous therapies in terms of specificity, effectiveness, and ease of delivery have led to numerous new product launches and approvals in this domain. Over 100 mAb products have been approved by the US FDA and the scope of therapeutic mAb applications is expected to grow further due to the development of antibody fragments, antibody derivatives, and bispecific antibodies that offer advanced treatment options.
Increased Number of Strategic Initiatives Presenting Lucrative Opportunities for Monoclonal Antibodies
The market is also favored by the strategic initiatives undertaken by key players for the development and marketing of mAb products. For instance, in October 2021, T-Cure Bioscience, Inc. collaborated with Atlas Antibodies AB for the production and supply of CT83 mAbs.
Similarly, in January 2022, Ono Pharmaceutical Co., Ltd. and Neurimmune AG collaborated on the creation of mAb drugs against new therapeutic targets for neurodegenerative diseases. Such initiatives are expected to open new growth opportunities and positively affect market growth.
Principal Consultant
High Development Costs of Monoclonal Antibodies Hindering Growth
High costs associated with the development of mAbs and the resultant increase in prices for mAb therapeutics can impede market growth in the near future. For instance, COVID-19 treatment mAbs such as Regeneron’s REGEN-COV (casirivimab and imdevimab), and GlaxoSmithKline & Vir Biotechnology’s sotrovimab cost around USD 1,250 and USD 2,100 per infusion, respectively. Such high drug prices can limit access to mAb therapies for large patient populations in developing countries and restrict mAbs adoption.
Expansion of the Healthcare Sector in the U.S. Will Drive the Adoption of Monoclonal Antibodies
North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research prospects, among other factors.
Moreover, increasing government expenditure for cancer research and the presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others, are expected to boost market growth.
Increasing Medical Tourism in Asia Pacific is Spurring Demand for Monoclonal Antibodies
Asia Pacific region is projected to exhibit the fastest growth rate in the forecast period due to the increasing disposable income, availability of a large patient pool for mAb cancer therapeutics, and rising focus on healthcare.
Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for mAbs.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In-vivo Production Type is expected to grow at a Significant Rate
In vivo production held the largest market share in 2021 due to its economic viability in long production runs and lower propensity for contamination with foreign antigens. In addition, the availability of serum-free culture media and semi-permeable membrane-based systems has increased the feasibility of biomanufacturing operations and is likely to accelerate segment growth. However, the production type is limited by variations in hybridoma characteristics that can lead to the denaturation or inactivation of antibodies and restrict segment growth.
In vivo production type is expected to grow at a significant rate in the forecast period due to its highly cost-effective production as compared to in vitro techniques and its ability to produce a high concentration of mAbs. These mAbs are used in the diagnostic industry, wherein cost considerations are of prime importance, and optimization of in vivo procedures can be done to increase the secretion of mAbs.
Demand for Monoclonal Antibodies in Hospitals to Gain Traction
The hospital end-use segment held the largest market share of 40.8% in 2021 due to the increasing adoption of mAbs for cancer treatment at hospitals. Rising healthcare expenditure across the world, increasing patient awareness levels, and availability of advanced hospital infrastructure in developed countries are factors expected to result in the dominance of the segment during the forecast period.
Specialty centers accounted for a significant market share in 2021 due to the increasing government support in recent years. For instance, the National Cancer Institute’s Cancer Centers Program is establishing standards for transdisciplinary cancer centers focused on the prevention, diagnosis, and treatment of various types of cancers. Such initiatives are expected to positively affect segment growth.
Oncology Segment to account for Dominant Application of Monoclonal Antibodies
The oncology segment dominated the applications market for mAbs and accounted for 50.1% of the market value in 2021. This can be attributed to the high number of regulatory approvals for mAbs aimed at cancer treatment. The surge in the incidence of cancer is a key factor anticipated to drive the growth of mAbs therapeutics as these can have minimal adverse effects as compared to other drugs and chemotherapy interventions. Currently, available mAb therapeutics include those targeted against non-small cell lung, brain tumor, ovarian, breast, gastric, melanoma, colorectal, Hodgkin’s lymphoma, and others.
Applications of mAbs for the treatment of autoimmune diseases are projected to grow at a lucrative rate due to the increasing prevalence of autoimmune conditions such as rheumatoid arthritis. Furthermore, with growth in the number of cytokine proteins identified in inflammatory pathways that can be targeted for disease mitigation, applications of mAbs in this domain are anticipated to witness growth.
Some of the start-ups in the monoclonal antibodies market include-
Key players in the Monoclonal Antibodies market are Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc.; Daiichi Sankyo Company, Limited; Abbott Laboratories; AstraZeneca plc; Eli Lilly And Company; Johnson & Johnson Services, Inc. and many more.
| Report Attributes | Details |
|---|---|
| Market Value in 2022 | US$ 208.32 Billion |
| Market Value in 2032 | US$ 647.01 Billion |
| Growth Rate | CAGR of 12% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global Monoclonal Antibodies market to expand at a 12% value CAGR by 2032.
The global Monoclonal Antibodies market is estimated at a market value of US$ 208.32 Billion.
The global Monoclonal Antibodies market is expected to garner a market value of US$ 647.01 Billion.
FMI has projected North America to be one of the key regions for the Monoclonal Antibodies market, with the US expected to account for over 46.2% of the North American market during the forecast period.
Novartis AG; Pfizer Inc; GlaxoSmithKline plc; Amgen Inc.; Merck & Co., Inc. are some prominent Monoclonal Antibodies manufacturers.
The human source type held the largest share and accounted for 54.07% of the market value in 2021.
1. Executive Summary | Monoclonal Antibodies Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Source Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Source Type, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Source Type, 2022 to 2032
5.3.1. Murine
5.3.2. Chimeric
5.3.3. Humanized
5.3.4. Human
5.4. Y-o-Y Growth Trend Analysis By Source Type, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Source Type, 2022 to 2032
6. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Production Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Production Type, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Production Type, 2022 to 2032
6.3.1. In Vivo
6.3.2. In Vitro
6.4. Y-o-Y Growth Trend Analysis By Production Type, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Production Type, 2022 to 2032
7. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2032
7.3.1. Oncology
7.3.2. Autoimmune Diseases
7.3.3. Infectious Diseases
7.3.4. Neurological Diseases
7.3.5. Others
7.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021
7.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
8. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End-use
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End-use, 2017 to 2021
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-use, 2022 to 2032
8.3.1. Hospitals
8.3.2. Specialty Centers
8.3.3. Others
8.4. Y-o-Y Growth Trend Analysis By End-use, 2017 to 2021
8.5. Absolute $ Opportunity Analysis By End-use, 2022 to 2032
9. Global Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia Pacific
9.3.5. Middle East & Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. The US.
10.2.1.2. Canada
10.2.2. By Source Type
10.2.3. By Production Type
10.2.4. By Application
10.2.5. By End-use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Source Type
10.3.3. By Production Type
10.3.4. By Application
10.3.5. By End-use
10.4. Key Takeaways
11. Latin America Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Source Type
11.2.3. By Production Type
11.2.4. By Application
11.2.5. By End-use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Source Type
11.3.3. By Production Type
11.3.4. By Application
11.3.5. By End-use
11.4. Key Takeaways
12. Europe Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. The UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Source Type
12.2.3. By Production Type
12.2.4. By Application
12.2.5. By End-use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Source Type
12.3.3. By Production Type
12.3.4. By Application
12.3.5. By End-use
12.4. Key Takeaways
13. Asia Pacific Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.1.4. Singapore
13.2.1.5. Thailand
13.2.1.6. Indonesia
13.2.1.7. Australia
13.2.1.8. New Zealand
13.2.1.9. Rest of Asia Pacific
13.2.2. By Source Type
13.2.3. By Production Type
13.2.4. By Application
13.2.5. By End-use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Source Type
13.3.3. By Production Type
13.3.4. By Application
13.3.5. By End-use
13.4. Key Takeaways
14. MEA Monoclonal Antibodies Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Source Type
14.2.3. By Production Type
14.2.4. By Application
14.2.5. By End-use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Source Type
14.3.3. By Production Type
14.3.4. By Application
14.3.5. By End-use
14.4. Key Takeaways
15. Key Countries Monoclonal Antibodies Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Source Type
15.1.2.2. By Production Type
15.1.2.3. By Application
15.1.2.4. By End-use
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Source Type
15.2.2.2. By Production Type
15.2.2.3. By Application
15.2.2.4. By End-use
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Source Type
15.3.2.2. By Production Type
15.3.2.3. By Application
15.3.2.4. By End-use
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Source Type
15.4.2.2. By Production Type
15.4.2.3. By Application
15.4.2.4. By End-use
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Source Type
15.5.2.2. By Production Type
15.5.2.3. By Application
15.5.2.4. By End-use
15.6. The UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Source Type
15.6.2.2. By Production Type
15.6.2.3. By Application
15.6.2.4. By End-use
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Source Type
15.7.2.2. By Production Type
15.7.2.3. By Application
15.7.2.4. By End-use
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Source Type
15.8.2.2. By Production Type
15.8.2.3. By Application
15.8.2.4. By End-use
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Source Type
15.9.2.2. By Production Type
15.9.2.3. By Application
15.9.2.4. By End-use
15.10. China
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Source Type
15.10.2.2. By Production Type
15.10.2.3. By Application
15.10.2.4. By End-use
15.11. Japan
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Source Type
15.11.2.2. By Production Type
15.11.2.3. By Application
15.11.2.4. By End-use
15.12. South Korea
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Source Type
15.12.2.2. By Production Type
15.12.2.3. By Application
15.12.2.4. By End-use
15.13. Singapore
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Source Type
15.13.2.2. By Production Type
15.13.2.3. By Application
15.13.2.4. By End-use
15.14. Thailand
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Source Type
15.14.2.2. By Production Type
15.14.2.3. By Application
15.14.2.4. By End-use
15.15. Indonesia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Source Type
15.15.2.2. By Production Type
15.15.2.3. By Application
15.15.2.4. By End-use
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Source Type
15.16.2.2. By Production Type
15.16.2.3. By Application
15.16.2.4. By End-use
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Source Type
15.17.2.2. By Production Type
15.17.2.3. By Application
15.17.2.4. By End-use
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Source Type
15.18.2.2. By Production Type
15.18.2.3. By Application
15.18.2.4. By End-use
15.19. South Africa
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Source Type
15.19.2.2. By Production Type
15.19.2.3. By Application
15.19.2.4. By End-use
15.20. Israel
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Source Type
15.20.2.2. By Production Type
15.20.2.3. By Application
15.20.2.4. By End-use
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Source Type
16.3.3. By Production Type
16.3.4. By Application
16.3.5. By End-use
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Novartis AG
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Pfizer Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. GlaxoSmithKline plc
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Amgen Inc.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Merck & Co., Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Daiichi Sankyo Company, Limited
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Abbott Laboratories
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. AstraZeneca plc
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Eli Lilly And Company
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Johnson & Johnson Services, Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Bayer AG
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Bristol Myers Squibb
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. F. Hoffman-La Roche Ltd.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Viatris Inc.
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.15. Biogen Inc.
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
17.1.16. Thermo Fisher Scientific, Inc.
17.1.16.1. Overview
17.1.16.2. Product Portfolio
17.1.16.3. Profitability by Market Segments
17.1.16.4. Sales Footprint
17.1.16.5. Strategy Overview
17.1.16.5.1. Marketing Strategy
17.1.17. Novo Nordisk A/S
17.1.17.1. Overview
17.1.17.2. Product Portfolio
17.1.17.3. Profitability by Market Segments
17.1.17.4. Sales Footprint
17.1.17.5. Strategy Overview
17.1.17.5.1. Marketing Strategy
17.1.18. Sanofi S.A.
17.1.18.1. Overview
17.1.18.2. Product Portfolio
17.1.18.3. Profitability by Market Segments
17.1.18.4. Sales Footprint
17.1.18.5. Strategy Overview
17.1.18.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Monoclonal Antibodies Market
